Back to today’s briefing

Story perspectives

FMT Trial Cuts Hepatic Encephalopathy Recurrence, Boosts Liver Health

1/18/2025

50 6

Summary

Story summary

A groundbreaking clinical trial at Virginia Commonwealth University revealed that fecal microbiota transplantation (FMT) dramatically lowers the recurrence of hepatic encephalopathy in cirrhosis patients, enhancing their quality of life. Additionally, research underscores the liver-boosting benefits of apples' flavonoids and fiber, indicating that small dietary adjustments can significantly support liver health.

1 of 1

Story summary

A groundbreaking clinical trial at Virginia Commonwealth University revealed that fecal microbiota transplantation (FMT) dramatically lowers the recurrence of hepatic encephalopathy in cirrhosis patients, enhancing their quality of life. Additionally, research underscores the liver-boosting benefits of apples' flavonoids and fiber, indicating that small dietary adjustments can significantly support liver health.